EARNINGS PER SHARE |
NOTE 9 – EARNINGS PER SHARE The following table presents earnings per share for the three and nine month periods ended September 30, 2022, and 2021.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended |
|
|
Nine months ended |
|
|
|
September 30, 2022 |
|
|
September 30, 2021 |
|
|
September 30, 2022 |
|
|
September 30, 2021 |
|
Basic: |
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) allocable to common stockholders |
|
$ |
15,171 |
|
|
$ |
11,773 |
|
|
$ |
46,080 |
|
|
$ |
42,014 |
|
Weighted average common shares outstanding |
|
|
16,056,366 |
|
|
|
14,384,285 |
|
|
|
16,301,500 |
|
|
|
14,393,853 |
|
Weighted average vested restricted stock units |
|
|
292 |
|
|
|
17 |
|
|
|
2,086 |
|
|
|
3,293 |
|
Weighted average shares |
|
|
16,056,658 |
|
|
|
14,384,302 |
|
|
|
16,303,586 |
|
|
|
14,397,146 |
|
Basic earnings (loss) per common share |
|
$ |
0.94 |
|
|
$ |
0.82 |
|
|
$ |
2.83 |
|
|
$ |
2.92 |
|
Diluted: |
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) allocable to common stockholders |
|
$ |
15,171 |
|
|
$ |
11,773 |
|
|
$ |
46,080 |
|
|
$ |
42,014 |
|
Weighted average common shares outstanding for: |
|
|
|
|
|
|
|
|
|
|
|
|
Basic earnings per common share |
|
|
16,056,658 |
|
|
|
14,384,302 |
|
|
|
16,303,586 |
|
|
|
14,397,146 |
|
Dilutive effects of the assumed exercise of stock options |
|
|
88,530 |
|
|
|
158,768 |
|
|
|
95,435 |
|
|
|
178,314 |
|
Dilutive effects of the assumed vesting of restricted stock units |
|
|
126,138 |
|
|
|
125,321 |
|
|
|
115,844 |
|
|
|
110,617 |
|
Dilutive effects of the assumed exercise of ESPP purchases |
|
|
1,905 |
|
|
|
921 |
|
|
|
1,922 |
|
|
|
2,015 |
|
Average shares and dilutive potential common shares |
|
|
16,273,231 |
|
|
|
14,669,312 |
|
|
|
16,516,787 |
|
|
|
14,688,092 |
|
Diluted earnings (loss) per common share |
|
$ |
0.93 |
|
|
$ |
0.80 |
|
|
$ |
2.79 |
|
|
$ |
2.86 |
|
Average shares not included in the computation of diluted earnings per share because they were antidilutive are shown in the following table for the three and nine month periods ended September 30, 2022, and 2021.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended |
|
|
Nine months ended |
|
|
|
September 30, 2022 |
|
|
September 30, 2021 |
|
|
September 30, 2022 |
|
|
September 30, 2021 |
|
Stock options |
|
|
275,471 |
|
|
|
291,680 |
|
|
|
204,982 |
|
|
|
298,629 |
|
Restricted stock units |
|
|
1 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Total antidilutive shares |
|
|
275,472 |
|
|
|
291,680 |
|
|
|
204,982 |
|
|
|
298,629 |
|
|